In recent days, Tempus AI announced a string of oncology-focused product advances, including FDA approval of its xT CDx tumor-only sequencing assay, major upgrades to its AI-enabled Next and Hub ...
Foundation Medicine, Inc., a global, patient-focused precision medicine company, today announced that it has received approvals from the U.S. Food and Drug Administration (FDA) for FoundationOne®CDx ...
-Recommended and maximum tolerated dose defined as 1.5 mg/kg for further study--Expansion cohort in head and neck squamous cell carcinoma added based on observed clinical activity--Clinical trial ...
U.S. Food and Drug Administration Approves FoundationOne®CDx as a Companion Diagnostic for Itovebi™ (inavolisib) to Identify Patients with Hormone Receptor-Positive, HER2-Negative Breast Cancer with a ...
--Data strongly support expanding development into mast cell driven diseases----Data presented in a late-breaking session at EAACI Annual Congress 2020-- CDX-0159 demonstrated a favorable safety ...
FoundationOne CDx has been approved as a companion diagnostic to identify patients with non–small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 ...
Add The Drive (opens in a new tab) More information Adding us as a Preferred Source in Google by using this link indicates that you would like to see more of our content in Google News results Luxury ...
Shares of Guardant Health (GH) traded higher on Wednesday after the U.S. Food and Drug Administration approved its blood-based cancer test, Guardant360 Liquid CDx. Designed to integrate genomic and ...
Zacks Investment Research on MSN
NTRA's Signatera CDx wins FDA nod in muscle-invasive bladder cancer
Natera, Inc. NTRA recently announced the FDA approval of Signatera CDx as a companion diagnostic (CDx) for use with adjuvant atezolizumab (Tecentriq) immunotherapy in patients with muscle-invasive ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results